- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methy
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]
| EU orphan designation number: | EU/3/09/715
|
| Active ingredient: | Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] |
| Indication: | Treatment of acute lymphoblastic leukaemia |
| Sponsor: | ARIAD Pharma Ltd
Brooklands Business Park, Wellington Way, Weybridge, KT13 0TT, United Kingdom |
| EU Centralised marketing authorisation: | A centralised EU marketing authorisation has been obtained under the name Iclusig on 01/07/2013 with the number EU/1/13/839 |
Public summary of scientific opinion
EPAR
European Commission procedures
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 04/02/2010 | Centralised Orphan - Designation | EMEA/OD/122/09 | (2010)788 of 02/02/2010 |
CONTACT
EU links
Directorate General Health & Consumers